US Patent

US11414397 — Somatostatin modulators and uses thereof

Method of Use · Assigned to Crinetics Pharmaceuticals Inc · Expires 2037-07-12 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects somatostatin modulators, including compounds, methods of making them, and uses in treating conditions that benefit from somatostatin modulation.

USPTO Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Drugs covered by this patent

paltusotine-hydrochloride (PALTUSOTINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4283`	—	paltusotine-hydrochloride
`U-4283`	—	paltusotine-hydrochloride

Patent Metadata

Patent number: US11414397
Jurisdiction: US
Classification: Method of Use
Expires: 2037-07-12
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Crinetics Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.